Triptorelin

Triptorelin is a synthetic decapeptide that mimics gonadotropin-releasing hormone (GnRH), a brain peptide that controls the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically to turn down the pituitary‑gonadal axis – the hormonal chain from brain to ovaries or testes. Research applications span central precocious puberty (CPP), where it halts early puberty, and advanced prostate cancer, where it cuts testosterone to castrate levels. In assisted reproduction, brief exposure triggers final egg maturation while reducing the risk of ovarian hyperstimulation syndrome (OHSS) Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial+3.

The compound was first studied decades ago for hormone‑dependent conditions like uterine fibroids and endometriosis. Its use has since widened to include long‑acting depot formulations that provide steady pituitary suppression over weeks to months Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+3. This makes it a practical alternative to daily injections or intravenous testing agents.

Most evidence comes from human trials and observational studies. In CPP diagnosis, a 100‑microgram injection – given under the skin or into muscle – reliably triggers an LH rise that confirms central activation of the axis Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial+3. For treatment, depot shots (3.75 mg monthly, 11.25 mg every 3 months, or 22.5 mg every 6 months) keep LH and estradiol or testosterone suppressed, slowing skeletal maturation and preserving adult height potential Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+4.

Triptorelin works as a GnRH agonist at the pituitary gland. When it first reaches the pituitary, it triggers a burst of LH and FSH – the “flare” phase. This acute response is used diagnostically: a single 100‑mcg injection raises LH within 30–120 minutes, confirming that the pituitary‑gonadal axis is active Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial+2.

With ongoing exposure from depot formulations, the pituitary GnRH receptors become desensitized. Continuous stimulation paradoxically shuts down further LH and FSH release Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+2. The downstream effect is a drop in sex steroids – estradiol in girls and testosterone in men – which explains its therapeutic role in suppressing puberty, endometriosis growth, and prostate tumor signaling.

In girls with CPP, 6‑month triptorelin formulations maintain estradiol suppression over years of treatment. LH responses to stimulation become blunted, and pubertal progression stalls GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis+1. In men with advanced prostate cancer, monthly triptorelin cuts testosterone to castrate levels within 4–8 weeks and keeps it there Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.

Beyond the pituitary, triptorelin may act directly on GnRH‑receptor‑positive cancer cells. In lab studies, it blocked estradiol‑driven growth signals in endometrial, ovarian, and breast cancer cell lines without interfering with the estrogen receptor itself Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.

Central precocious puberty (CPP)

• Halts breast development, menses, and testicular enlargement within months of starting monthly or longer‑interval depot therapy Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+2.
• Slows growth velocity and bone‑age advancement, preserving final adult height. Observational studies estimate gains of roughly 3.5–4.5 cm Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+1.
• Diagnostic stimulation with 100 mcg identifies CPP with high sensitivity; peak LH ≥5–6 IU/L after injection supports the diagnosis Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial+3.

Assisted reproduction

• As a final oocyte maturation trigger (0.2–0.3 mg), it induces an LH surge comparable to hCG while markedly lowering OHSS risk GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis+3.
• In prolon‑ded down‑regulation protocols, depot triptorelin before IVF improves outcomes in endometriosis or adenomyosis, though evidence comes mainly from case series Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report+1.

Prostate cancer

• Monthly 3.75 mg injections reduce testosterone to castrate levels in over 90% of men by day 57 and maintain suppression for months Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer+1.

Other indications

• Uterine fibroid and endometriosis symptom relief (moderate evidence from RCTs) Medical Treatment for Endometriosis: One Size Does Not Fit All.
• Height preservation in children with early puberty and short stature, often combined with growth hormone Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature.

Research protocols vary by indication, but several standard regimens are well documented.

• CPP diagnosis: A single 100 mcg subcutaneous or intramuscular injection is given; LH is measured at baseline and serially up to 120 minutes. Both routes produce similar diagnostic accuracy Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial+2.
• CPP treatment – monthly depot: 3.75 mg intramuscularly every 4 weeks. This schedule suppresses LH and estradiol in most children within 3 months and is used for 1–3 years or longer Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+2.
• CPP treatment – extended‑interval depot: 11.25 mg every 12 weeks or 22.5 mg every 24 weeks, offering comparable suppression while reducing injection frequency Efficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study+3.
• IVF trigger: 0.2–0.3 mg subcutaneously as a single dose when leading follicles reach ≥18 mm; oocyte retrieval follows about 36 hours later Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial+1.
• Endometriosis/adenomyosis down‑regulation: Depot 3.75 mg monthly for 1–3 months before ovarian stimulation or embryo transfer Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report+2.

Timing details are crucial. For diagnostic testing, extending blood sampling to 120 minutes captures late LH peaks that a shorter window might miss Subcutaneous Gonadotropin-Releasing Hormone Agonist (Triptorelin) Test for Diagnosing Precocious Puberty+1. In long‑term suppression, some clinicians adjust the injection interval based on individual response, lengthening to 5 weeks when suppression is deep or shortening to 3 weeks if breakthrough puberty occurs Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature.

Triptorelin comes in two main forms: an immediate‑release preparation for diagnostics/triggers and a long‑acting depot for sustained suppression.

Non‑depot (lyophilized) vials

• Research peptide handling typically uses bacteriostatic water for multi‑dose vials or sterile water for single use [community protocol].
• Gently add the diluent down the vial wall and swirl; do not shake.
• Store unreconstituted vials refrigerated (2–8 °C) or frozen (−20 °C) protected from light.
• After reconstitution, keep at 2–8 °C and use within 21–28 days (bacteriostatic water) or within 24–72 hours (sterile water) if aseptic technique is maintained [community protocol].
• An interactive calculator on the page handles dilution math for preparing specific doses like 100 mcg; refer to that tool rather than static tables.

Depot microsphere formulations

• Depot kits (3.75 mg, 11.25 mg, 22.5 mg) must be reconstituted only with the manufacturer‑supplied diluent immediately before injection. The resulting milky suspension cannot be stored and must be administered promptly Idiopathic Central Precocious Puberty+2.
• Bring the kit to room temperature, mix per instructions, and inject without delay to preserve the release profile.
• These intramuscular depot products are not interchangeable with simple aqueous peptide solutions.

Always use sterile technique regardless of formulation.

Triptorelin’s interaction profile is driven by its endocrine effects, not liver metabolism. It is a peptide, so CYP enzyme interactions are minimal.

Gonadotropins and hCG

• In IVF, triptorelin is intentionally combined with FSH or hMG for controlled ovarian stimulation. Adding hCG as a dual trigger may increase oocyte yield in poor responders, but its effect on OHSS risk is not clearly established Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial+1.

Other GnRH analogs

• Combining triptorelin with another GnRH agonist or antagonist is usually unnecessary and can confuse suppression monitoring GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis+1.

Sex‑steroid add‑back

• Estrogen, progesterone, or testosterone may be added to manage hypoestrogenic symptoms during long‑term suppression, but this can counteract the intended endocrine goal if not carefully planned Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report+1.

Neuropsychiatric medications

• Pharmacovigilance data show elevated reporting of depression and suicide/self‑injury with GnRH agonists, so patients on antidepressants or with mood disorders warrant closer monitoring Association of GnRH agonists with depression and suicide/self-injury: a FAERS pharmacovigilance study.

Supplements

• DHEA, phytoestrogens (soy isoflavones, black cohosh), or testosterone boosters may oppose suppression and confound hormone measurements [community protocol].
• Calcium and vitamin D support bone health during prolonged hypoestrogenic periods without interacting with triptorelin.

Triptorelin is not typically “cycled” in the bodybuilding sense. Its clinical use follows three broad patterns:

Single‑dose trigger – A one‑time injection for IVF oocyte maturation, with no need for cycling Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial.

Continuous suppression – Monthly or longer‑interval depots are given without interruption for months to years in CPP or prostate cancer Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+2. The goal is sustained pituitary desensitization, not alternating on/off periods.

Finite suppression blocks – For endometriosis or adenomyosis, a planned 1–3 months of depot injections precede fertility treatment, after which the drug is stopped and the axis allowed to recover Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report+1.

Receptors do not develop “tolerance” in the stimulant sense; continued exposure deepens suppression after the initial flare Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence. However, breaks may be considered if side effects (hot flashes, mood changes, bone loss) become burdensome. When stopped, pubertal or gonadal function gradually returns, though the exact timeline varies Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+1.

In CPP, inadequate suppression – signaled by breakthrough growth, menses, or rising LH – means the dose or interval needs adjustment, not cycling Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature+1.

Research explores several rational combinations with triptorelin:

With growth hormone (CPP/short stature)

• Adding GH to triptorelin in children with CPP or early puberty may further improve predicted adult height; observational series report greater short-term height gains, but data on final adult height gain are limited Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence.

With gonadotropins (IVF)

• Standard ovarian stimulation stacks triptorelin (for pituitary control) with FSH or hMG. In antagonist cycles, dual trigger (triptorelin + hCG) may be used for poor responders, though benefit is variable Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial+1.

With hCG (dual trigger)

• Combining a 0.2‑mg triptorelin trigger with low‑dose hCG (1,000–2,500 IU) is studied in IVF to support the luteal phase without increasing OHSS in high responders, but evidence for improved live birth is mixed ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025†+1.

With sex‑steroid add‑back

• In endometriosis or transgender medicine, small doses of estrogen or testosterone may be added to offset hypoestrogenic symptoms while maintaining suppression, though careful monitoring is required Medical Treatment for Endometriosis: One Size Does Not Fit All.

Stacking with androgenic substances is counterproductive if the goal is pituitary suppression.

Triptorelin is an FDA‑approved prescription medication for central precocious puberty and advanced prostate cancer. Branded depot products (e.g., Triptodur, Trelstar) are licensed for monthly, 3‑month, and 6‑month administration Idiopathic Central Precocious Puberty+2. It is not a controlled substance under U.S. federal law.

Internationally, triptorelin is widely authorized. The UK’s MHRA recognizes Decapeptyl SR for CPP Efficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study, and European practice routinely uses Diphereline depot Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence. China has approved local microsphere and 6‑month formulations Efficacy and safety of triptorelin 3-month formulation in Chinese children with central precocious puberty: a phase 3, open-label, single-arm study+1. It is prescription‑only everywhere; import rules typically require a valid prescription.

For athletes, triptorelin falls under the World Anti‑Doping Agency (WADA) Prohibited List as a gonadotrophin‑releasing hormone analogue. It is banned at all times. Analytical methods to detect triptorelin metabolites in urine are published for doping control The Impact of Triptorelin on Hormone Levels in Human and Its Metabolite Confirmation Using Liquid Chromatography-Ion Trap/Time-of-Flight Mass Spectrometry (LC/MS-IT-TOF) and Liquid Chromatography-Orbitrap (LC-Orbitrap) for Doping Control Analysis+1. Therapeutic Use Exemption (TUE) is required for medical use in competition.

Common effects

• Hot flashes, headache, injection‑site pain, and fatigue occur frequently but are usually mild. In CPP, adverse events rarely lead to discontinuation Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence+3.
• The intended hormonal suppression itself causes hypoestrogenic symptoms (vaginal dryness, reduced libido, mood swings) during treatment.

Mood and psychiatric signals

• FAERS pharmacovigilance analysis found disproportionate reporting of depression and suicide/self‑injury with GnRH agonists, with earlier onset in females and younger patients. This is a signal, not proven causality Association of GnRH agonists with depression and suicide/self-injury: a FAERS pharmacovigilance study.
• Regular mood screening is recommended, especially in adolescents or those with pre‑existing vulnerability.

Injection‑site reactions

• Depot products can rarely cause sterile abscess or granuloma. One case report describes recurrent reactions to both leuprorelin and triptorelin MON-069 Uncontrolled Central Precocious Puberty Patient Against GnRH Agonist, After Showing Granuloma Formation and Sterile Abscess to Both Leuprorelin Acetate and Triptorelin Actate.

Bone and metabolic

• Prolonged hypoestrogenism may reduce bone mineral density. Pediatric patients show improvement in predicted adult height, but skeletal monitoring is still advised Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence.
• Weight gain and BMI changes are occasionally reported in children on GnRHa therapy Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence.

Contraindications

• Known hypersensitivity to triptorelin or other GnRH agonists.
• Pregnancy (outside specific IVF trigger protocols).
• Unstable severe depression or suicidality, given the signal data. Close monitoring is mandatory in such cases.